Onconic Therapeutics Inc. (KOSDAQ:476060)
21,250
-200 (-0.93%)
Jun 27, 2025, 3:30 PM KST
Onconic Therapeutics Balance Sheet
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 44,480 | 43,000 | 30,100 | 27,316 | 18,861 |
Cash & Short-Term Investments | 44,480 | 43,000 | 30,100 | 27,316 | 18,861 |
Cash Growth | 47.77% | 42.85% | 10.19% | 44.83% | - |
Accounts Receivable | 7,581 | 7,326 | -0 | 841.52 | 173.71 |
Other Receivables | 328.78 | 254.84 | 366.74 | 5.08 | 2.9 |
Receivables | 7,909 | 7,581 | 366.74 | 846.6 | 176.61 |
Other Current Assets | 1,523 | 1,554 | 291.85 | 8.22 | 10.43 |
Total Current Assets | 53,912 | 52,134 | 30,759 | 28,171 | 19,048 |
Property, Plant & Equipment | 3,161 | 3,285 | 3,568 | 2,619 | 263.6 |
Other Intangible Assets | 0.98 | 1.27 | 2.45 | 3.63 | 4.8 |
Long-Term Deferred Tax Assets | 5,355 | 5,355 | 3,100 | - | - |
Other Long-Term Assets | 137.95 | 137.95 | 118.38 | 113.14 | 110.6 |
Total Assets | 62,567 | 60,913 | 37,548 | 30,907 | 19,427 |
Accounts Payable | 1,054 | 708.67 | - | - | - |
Accrued Expenses | 65.56 | 65.56 | 82.14 | - | - |
Current Portion of Leases | 187.53 | 188.95 | 154.27 | 50.72 | 135.52 |
Current Income Taxes Payable | 22.39 | 463.39 | - | - | - |
Other Current Liabilities | 2,766 | 3,339 | 42,977 | 26,539 | 392.14 |
Total Current Liabilities | 4,095 | 4,765 | 43,214 | 26,590 | 527.66 |
Long-Term Leases | 76.17 | 119.52 | 199.4 | - | 53.52 |
Other Long-Term Liabilities | - | 0 | 25.14 | 26,229 | 26,823 |
Total Liabilities | 4,197 | 4,895 | 43,442 | 52,844 | 27,405 |
Common Stock | 5,441 | 5,402 | 2,890 | 2,890 | 2,890 |
Additional Paid-In Capital | 37,703 | 87,419 | 7,146 | 7,146 | 7,146 |
Retained Earnings | 12,776 | -39,121 | -31,019 | -32,688 | -18,256 |
Comprehensive Income & Other | 2,451 | 2,319 | 1,294 | 715.69 | 243.21 |
Total Common Equity | 58,370 | 56,019 | -19,690 | -21,937 | -7,978 |
Shareholders' Equity | 58,370 | 56,019 | -5,894 | -21,937 | -7,978 |
Total Liabilities & Equity | 62,567 | 60,913 | 37,548 | 30,907 | 19,427 |
Total Debt | 263.7 | 308.47 | 353.66 | 50.72 | 189.04 |
Net Cash (Debt) | 44,217 | 42,691 | 29,747 | 27,265 | 18,672 |
Net Cash Growth | 48.64% | 43.52% | 9.10% | 46.02% | - |
Net Cash Per Share | 4081.51 | 5221.54 | 51468.03 | 47172.73 | 32609.36 |
Filing Date Shares Outstanding | 10.88 | 10.8 | 9.21 | 0.58 | 0.57 |
Total Common Shares Outstanding | 10.88 | 10.8 | 9.21 | 0.58 | 0.57 |
Working Capital | 49,817 | 47,369 | -12,454 | 1,581 | 18,520 |
Book Value Per Share | 5363.96 | 5185.03 | -2138.45 | -37953.20 | -13932.19 |
Tangible Book Value | 58,369 | 56,018 | -19,692 | -21,941 | -7,982 |
Tangible Book Value Per Share | 5363.87 | 5184.91 | -2138.71 | -37959.47 | -13940.57 |
Land | 570.58 | 570.58 | 570.58 | - | - |
Buildings | 1,617 | 1,617 | 1,617 | - | - |
Machinery | 1,155 | 1,138 | 1,033 | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.